Literature DB >> 19259714

Stereoselective epoxidation of cis-propenylphosphonic acid to fosfomycin by a newly isolated bacterium Bacillus simplex strain S101.

Fuhong Xie1, Yapeng Chao, Zhiquan Xue, Xiuqing Yang, Guoqing Zhang, Jiaji Shi, Shijun Qian.   

Abstract

In industry, fosfomycin is mainly prepared via chemical epoxidation of cis-propenylphosphonic acid (cPPA). The conversion yield of fosfomycin is less than 50% in the whole process and a large quantity of waste is produced. Biotransformation by microorganisms is an alternative method of preparation. This kind of conversion is more delicate, environmentally friendly, and the conversion yield of fosfomycin would be higher. In this work, an aerobic bacterium capable of transforming cPPA to fosfomycin was isolated. The organism, designated as strain S101, was identified as Bacillus simplex by morphological and physiological characteristics as well as by analysis of the gene encoding the 16S rRNA. Fosfomycin was assayed by two means, bioassay and gas chromatography (GC). Glycerol was a good carbon source for growth and cPPA conversion of strain S101. When cPPA was used as the sole carbon source, neither growth nor conversion to fosfomycin occurred. The optimum cPPA concentration in the conversion medium was 2,000 microg ml(-1). After 6 days of incubation, the concentration of fosfomycin reached its maximum level (1,838.2 microg ml(-1)), with a conversion ratio of 81.3%. Air was indispensable for the growth but not for the conversion to fosfomycin. Furthermore, vanadium ions were found to be essential for the conversion. High concentrations of cPPA had fewer inhibitory effects on the growth of strain S101.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259714     DOI: 10.1007/s10295-009-0546-7

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  29 in total

1.  Studies on the biosynthesis of fosfomycin. 4. The biosynthetic origin of the methyl group of fosfomycin.

Authors:  T Kuzuyama; T Hidaka; K Kamigiri; S Imai; H Seto
Journal:  J Antibiot (Tokyo)       Date:  1992-11       Impact factor: 2.649

2.  Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin.

Authors:  Anucha Apisarnthanarak; Linda M Mundy
Journal:  Int J Infect Dis       Date:  2006-07-28       Impact factor: 3.623

3.  Studies on the biosynthesis of fosfomycin. 2. Conversion of 2-hydroxypropyl-phosphonic acid to fosfomycin by blocked mutants of Streptomyces wedmorensis.

Authors:  H Seto; T Hidaka; T Kuzuyama; S Shibahara; T Usui; O Sakanaka; S Imai
Journal:  J Antibiot (Tokyo)       Date:  1991-11       Impact factor: 2.649

Review 4.  Brief overview of single-dose therapy for uncomplicated urinary tract infections.

Authors:  R R Bailey
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

5.  Structural insight into antibiotic fosfomycin biosynthesis by a mononuclear iron enzyme.

Authors:  Luke J Higgins; Feng Yan; Pinghua Liu; Hung-wen Liu; Catherine L Drennan
Journal:  Nature       Date:  2005-07-13       Impact factor: 49.962

Review 6.  Fosfomycin trometamol.

Authors:  D S Reeves
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

Review 7.  Management of lower urinary tract infections.

Authors:  R R Bailey
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Oxygenase activity in the self-hydroxylation of (s)-2-hydroxypropylphosphonic acid epoxidase involved in fosfomycin biosynthesis.

Authors:  Pinghua Liu; Mark P Mehn; Feng Yan; Zongbao Zhao; Lawrence Que; Hung-wen Liu
Journal:  J Am Chem Soc       Date:  2004-08-25       Impact factor: 15.419

9.  Optimum culture conditions for the epoxidation of cis-propenylphosphonate to fosfomycin by Cellvibrio gilvus.

Authors:  K Aisaka; T Ohshiro; T Uwajima
Journal:  Appl Microbiol Biotechnol       Date:  1992-01       Impact factor: 4.813

10.  Production of fosfomycin (phosphonomycin) by Pseudomonas syringae.

Authors:  J Shoji; T Kato; H Hinoo; T Hattori; K Hirooka; K Matsumoto; T Tanimoto; E Kondo
Journal:  J Antibiot (Tokyo)       Date:  1986-07       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.